This result was not influenced by the dose of dipyridamole or type of presenting vascular disease .
For patients who presented with arterial vascular disease , there was no evidence that dipyridamole , in the presence or absence of another antiplatelet drug reduced the risk of vascular death , though it reduces the risk of further vascular events .
This benefit was found only in patients presenting after cerebral ischaemia .
There was no evidence that dipyridamole alone was more efficacious than aspirin
BACKGROUND Patients with limited cerebral ischaemia of arterial origin are at risk of serious vascular events ( 4 % to 11 % annually ) .
Aspirin reduces that risk by 13 % .
In one trial , adding dipyridamole to aspirin was associated with a 22 % risk reduction compared with aspirin alone .
OBJECTIVES To assess the efficacy and safety of dipyridamole versus control in the secondary prevention of vascular events in patients with vascular disease .
Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia.
There is continuing debate about the relative efficacy of low ( < 100 mg per day ) , medium ( 300 to 325 mg per day ) , and high ( > 900 mg per day ) doses of aspirin in patients after a transient ischaemic attack or non-disabling stroke . The purpose of this study was to resolve the issue . Thus a minimeta- analysis was performed on data from 10 r and omised trials of aspirin only v control treatment in 6171 patients after a transient ischaemic attack or nondisabling stroke . The data on the trials were listed in an appendix of the report on the second cycle of the Antiplatelet Trialists ' Collaboration . There was virtually no difference in relative risk reduction for low , medium , and high doses of aspirin ( 13 % , 9 % , and 14 % respectively ) . This equivalence corresponds with the results of the UK-TIA trial in a direct comparison of 300 and 1200 mg . The Dutch TIA trial showed no difference in efficacy of 30 and 283 mg . It is concluded that aspirin at any dose above 30 mg daily prevents 13 % ( 95 % confidence interval 4 - 21 ) of vascular events and that there is a need for more efficacious drugs
This result was not influenced by the dose of dipyridamole or type of presenting vascular disease .
For patients who presented with arterial vascular disease , there was no evidence that dipyridamole , in the presence or absence of another antiplatelet drug reduced the risk of vascular death , though it reduces the risk of further vascular events .
This benefit was found only in patients presenting after cerebral ischaemia .
There was no evidence that dipyridamole alone was more efficacious than aspirin
BACKGROUND Patients with limited cerebral ischaemia of arterial origin are at risk of serious vascular events ( 4 % to 11 % annually ) .
Aspirin reduces that risk by 13 % .
In one trial , adding dipyridamole to aspirin was associated with a 22 % risk reduction compared with aspirin alone .
OBJECTIVES To assess the efficacy and safety of dipyridamole versus control in the secondary prevention of vascular events in patients with vascular disease .